FOMX Foamix Pharmaceuticals Ltd.

3.48
-0.86  -20%
Previous Close 4.34
Open 3.58
Price To Book 3.52
Market Cap 212,293,666
Shares 61,003,927
Volume 9,877,116
Short Ratio
Av. Daily Volume 1,265,247
Stock charts supplied by TradingView

NewsSee all news

  1. Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and

  2. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  3. Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review

  4. Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and

  5. Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that, together with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 2, 2020.
FMX103
Papulopustular rosacea
FDA Approval announced October 18, 2019.
FMX101
Acne
Phase 2 data released December 2015
FDX104
Acne-like rash in cancer patients
Update to be provided as it materializes.
FDX102
Impetigo
Phase 2 commencement of enrolment announced September 19, 2019.
FCD105
Acne

Latest News

  1. Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and

  2. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  3. Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review

  4. Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and

  5. Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that, together with

  6. Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company, today

  7. Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company, today announced it will

  8. Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing

  9. Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate

  10. Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing